Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 EUR | -1.06% |
|
+13.59% | +62.50% |
05-29 | NFL Biosciences: study with CEA presented at congress | CF |
05-21 | NFL Biosciences receives positive feedback from the FDA | CF |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 |
---|---|---|---|
Capitalization 1 | 22.71 | 22.71 | - |
Enterprise Value (EV) 1 | 22.71 | 22.51 | 20.11 |
P/E ratio | - | - | - |
Yield | - | - | - |
Capitalization / Revenue | 114 x | - | - |
EV / Revenue | 114 x | - | - |
EV / EBITDA | - | - | - |
EV / FCF | -6.19 x | -4.5 x | -2.61 x |
FCF Yield | -16.2% | -22.2% | -38.3% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 9,705 | 9,705 | - |
Reference price 2 | 2.340 | 2.340 | 2.340 |
Announcement Date | 29/03/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 |
---|---|---|---|
Net sales 1 | 0.2 | - | - |
EBITDA | - | - | - |
EBIT 1 | -4.23 | -4.7 | -7.8 |
Operating Margin | -2,115.1% | - | - |
Earnings before Tax (EBT) | - | - | - |
Net income | - | - | - |
Net margin | - | - | - |
EPS | - | - | - |
Free Cash Flow 1 | -3.3 | -5 | -7.7 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 29/03/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 |
---|---|---|---|
Net Debt 1 | - | - | - |
Net Cash position 1 | 2.3 | 0.2 | 2.6 |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow 1 | -3.3 | -5 | -7.7 |
ROE (net income / shareholders' equity) | - | - | - |
ROA (Net income/ Total Assets) | - | - | - |
Assets | - | - | - |
Book Value Per Share | - | - | - |
Cash Flow per Share 2 | -0.7000 | -0.9000 | -1.500 |
Capex 1 | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 29/03/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+62.50% | 24.26M | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+2.13% | 13.54B | |
+66.67% | 15.19B |
- Stock Market
- Equities
- ALNFL Stock
- Financials NFL Biosciences